A new therapy that combines two existing drugs shows promise for patients with inflammatory bowel disease who have exhausted ...
Key Takeaways A new combination therapy might better help people with inflammatory bowel diseaseThe combination drug improved ...
JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn's disease ...
If you’re sipping on coconut water this summer to stay hydrated, you may be doing your gut a favor, too, without even ...
Investor's Business Daily on MSN
How this biotech scored 'a clear win' where Bristol Myers failed
Cytokinetics stock surged Tuesday on positive results in a key heart disease where its chief rival, Bristol's Camzyos, previously failed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results